BOLT
Market cap | $43.47 Million |
---|---|
Enterprise Value | $-38,504,376.00 |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-1.83 |
Beta | 1.17 |
Outstanding Shares | 38,127,740 |
Avg 30 Day Volume | 145,768 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -0.63 |
---|---|
PEG | 6.0 |
Price to Sales | - |
Price to Book Ratio | 0.58 |
Enterprise Value to Revenue | -4.89 |
Enterprise Value to EBIT | 0.51 |
Enterprise Value to Net Income | 0 |
Total Debt to Enterprise | -0.53 |
Debt to Equity | 0.18 |
No data
No data
Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjug...